Human & Experimental Toxicology · 2023 · 12 citations · 44 references
MedicinePharmacologyPharmacotherapyCardio-oncologyChemotherapyMolecular PharmacologyCardiac MedicationsCardiac PharmacotherapyCardiotoxicity ManagementCardiovascular DiseaseCardiovascular PharmacologyEndothelial DysfunctionCardioprotective TherapyCardiotoxicityCardiotoxicity MitigationHypoxia-inducible Factor RegulationHypoxia-inducible Factor SignalingMechanisms Of Cardiac InjuryVascular Endothelial Growth FactorVascular Endothelial Growth Factor Signaling
BACKGROUND: Cyclophosphamide (CP) is a commonly used chemotherapeutic and immunosuppressive alkylating agent. However, cardiac adverse effects of CP interfere with its clinical benefit. Cardio-oncology research is currently an important issue and finding effective cardiopreserving agents is a critical need. For the first time, we aimed to detect if dapagliflozin (DAP) could ameliorate CP-induced cardiac injury and investigated the role of hypoxia inducible factor α (HIF1α)/vascular endothelial growth factor (VEGF)/endothelial nitric oxide synthase (eNOS) pathway. METHODS: Forty male Wistar albino rats were included in the current model. Studied groups are: control group; CP-induced cardiotoxicity group; CP group treated with DAP; CP group treated with DAP and administered a nitric oxide synthase inhibitor; nitro-ω-L-arginine (L-NNA) before DAP to explore the role of eNOS. RESULTS: Our data revealed that CP could induce cardiac damage as manifested by significant increases in cardiac enzymes, blood pressure, malondialdehyde (MDA), tumor necrosis factor alpha (TNFα), HIF1α, sodium glucose co-transporter 2 (SGLT2) and cleaved caspase-3 levels with toxic histopathological changes. However, there are significant decreases in reduced glutathione (GSH), total antioxidant capacity (TAC), VEGF, and eNOS. On the opposite side, co-administration of DAP showed marked improvement of CP-induced cardiac damage that may be due to its ability to inhibit SGLT2, antioxidant, anti-inflammatory and anti-apoptotic properties. Results showed decreasing the cardioprotective effect of DAP on administration of L-NNA, reflecting the critical effect of eNOS in mediating such protection. CONCLUSION: DAP could reduce CP cardiotoxicity based upon its ability to modulate SGLT2 and HIF1α/VEGF/eNOS signaling pathway.
44
Piangkwan Sa‐nguanmoo, Pongpan Tanajak, Sasiwan Kerdphoo et al. · Toxicology and Applied Pharmacology · 2017 · 275 citations
Vascular Endothelial Growth Factor Modulates Skeletal Myoblast Function
Antonia Germani, Anna Di Carlo, Antonella Mangoni et al. · American Journal Of Pathology · 2003 · 237 citations · Full text